Hypercoagulable Thrombin Generation Correlates with High-Risk Clinical Features and Venous Thrombosis Recurrence

Following venous thromboembolism (VTE), predictive biomarker testing for risk assessment is hampered by the presence of anticoagulation. This study aims to remove in vitro interference caused by direct oral anticoagulants (DOACs) with DOAC-Stop, enabling thrombin generation testing during anticoagulation. Platelet-poor plasma was collected approximately 3 months after VTE diagnosis from adults who were therapeutically anticoagulated with apixaban or rivaroxaban. Thrombin generation testing was performed using ST-Genesia ThromboScreen, following use of DOAC-Stop. A total of 251 patients were included (mean age 55.4 years, 54.2% male). Patients with thrombophilia and/or family history of VTE demonstrated hypercoagulable thrombin generation parameters. A total of 165 patients (65.7%) were classified as clinically “high risk,” defined as one or more of unprovoked pulmonary embolism (PE) and/or proximal deep vein thrombosis (DVT), family history of VTE, personal prior history of VTE, and hereditary thrombophilia, with remaining cases considered “low-risk” VTE. The “high-risk” group demonstrated increased peak height, endogenous thrombin potential, and velocity index compared with the “low-risk” cohort. About 52.2% (n = 131/251) of all patients subsequently ceased anticoagulation, with five episodes of unprovoked recurrence occurring within 1 year of cessation. These patients had higher median peak height (139.4 vs. 104.6%, p = 0.043, percentile difference − 34.8, 95% confidence interval (CI): [− 68.4, − 1.81]) and ETP (119.5 vs. 103.7%, p = 0.006, percentile difference: − 27.5, 95% CI: [− 43.5, − 11.3]) without thrombomodulin. This study provides evidence that thrombin generation testing after DOAC-Stop can identify hypercoagulable VTE patients without interrupting anticoagulation. Thrombin generation was increased in several groups with clinical risk factors associated with hypercoagulability. Key thrombin generation parameters were increased and associated with unprovoked VTE recurrence in patients who later stopped anticoagulation. Larger confirmatory studies are required.

Authors

Institutions

Publication Details

Journal
Seminars in Thrombosis and Hemostasis
Published
2026-11-19
DOI
https://doi.org/10.1055/a-2982-1789
Primary Topic
Venous Thromboembolism Diagnosis and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Hypercoagulable Thrombin Generation Correlates with High-Risk Clinical Features and Venous Thrombosis Recurrence

Prahlad W. Ho, Julie Wang, Rowena Brook, Hui Yin Lim et al.
Seminars in Thrombosis and Hemostasis
Venous Thromboembolism Diagnosis and Management
article

Hypercoagulable Thrombin Generation Correlates with High-Risk Clinical Features and Venous Thrombosis Recurrence

Prahlad W. Ho, Julie Wang, Rowena Brook, Hui Yin Lim, Vincent Lu
article en

Abstract

Following venous thromboembolism (VTE), predictive biomarker testing for risk assessment is hampered by the presence of anticoagulation. This study aims to remove in vitro interference caused by direct oral anticoagulants (DOACs) with DOAC-Stop, enabling thrombin generation testing during anticoagulation. Platelet-poor plasma was collected approximately 3 months after VTE diagnosis from adults who were therapeutically anticoagulated with apixaban or rivaroxaban. Thrombin generation testing was performed using ST-Genesia ThromboScreen, following use of DOAC-Stop. A total of 251 patients were included (mean age 55.4 years, 54.2% male). Patients with thrombophilia and/or family history of VTE demonstrated hypercoagulable thrombin generation parameters. A total of 165 patients (65.7%) were classified as clinically “high risk,” defined as one or more of unprovoked pulmonary embolism (PE) and/or proximal deep vein thrombosis (DVT), family history of VTE, personal prior history of VTE, and hereditary thrombophilia, with remaining cases considered “low-risk” VTE. The “high-risk” group demonstrated increased peak height, endogenous thrombin potential, and velocity index compared with the “low-risk” cohort. About 52.2% (n = 131/251) of all patients subsequently ceased anticoagulation, with five episodes of unprovoked recurrence occurring within 1 year of cessation. These patients had higher median peak height (139.4 vs. 104.6%, p = 0.043, percentile difference − 34.8, 95% confidence interval (CI): [− 68.4, − 1.81]) and ETP (119.5 vs. 103.7%, p = 0.006, percentile difference: − 27.5, 95% CI: [− 43.5, − 11.3]) without thrombomodulin. This study provides evidence that thrombin generation testing after DOAC-Stop can identify hypercoagulable VTE patients without interrupting anticoagulation. Thrombin generation was increased in several groups with clinical risk factors associated with hypercoagulability. Key thrombin generation parameters were increased and associated with unprovoked VTE recurrence in patients who later stopped anticoagulation. Larger confirmatory studies are required.

Seminars in Thrombosis and Hemostasis
The University of Melbourne (AU), Northern Health (AU), Northern Hospital (AU), Monash University (AU)
Venous Thromboembolism Diagnosis and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon